Rolinsatamab ELISA Kit (DB801018)

Даташит Поделиться продуктом Копировать информацию

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	DB801018
Тип образца	Plasma, Serum
Чувствительность	0.156 μg/ml
Диапазон	0.31-5 μg/mL
Номер доступа	P16471
Применения	ELISA
Метод обнаружения	Colorimetric
Тип анализа	Quantitative
Восстановление	80-120%
Доставка	2-8 ℃
Устойчивость и хранение	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Характеристики	Rolinsatamab
Альтернативные названия	PR-1594804, h16f, ABBV-176, DC-1630993, h16f, Rolinsatamab talirine, 2095467-30-2
Фон	Prolactin receptor (Rolinsatamab) is a ~69 kDa protein. This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling.
Ссылки	1. Anderson MG, et al. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition. BMC Cancer. 2021;21(1):681. Published 2021 Jun 9. [DB801018] 2. Lemech C, et al. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors. Invest New Drugs. 2020;38(6):1815-1825. [DB801018] 3. Mukherjee A, et al. Targeted Therapy in Breast Cancer: Advantages and Advancements of Antibody-Drug Conjugates, a Type of Chemo-Biologic Hybrid Drugs. Cancers (Basel). 2024;16(20):3517. Published 2024 Oct 17. [DB801018] 4. Chervin AS, et al. ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies. Mol Cancer Ther. 2023;22(8):903-912. [DB801018] 5. Zhang J, et al. The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer. J Exp Clin Cancer Res. 2024;43(1):173. Published 2024 Jun 20. View More [DB801018]
Примечание	For Research Use Only.